Peptide Synthesis Market Size & Share, by Product (Equipment, Reagents & Consumables); Technology (Solid Phase, Liquid Phase, Hybrid & Recombinant); End-user {Pharmaceutical & Biotechnology Companies, Contract Development & Manufacturing Organization (CDMO), Research Institutes} - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

• Escalating Usage of Peptides in Pharmaceutical Drugs Along with A Rise in FDA Approval- Peptides offer fewer side effects and can be absorbed quickly into the body.  Moreover, they are more cost-friendly to produce and are much more stable as compared to traditional drug substances, as a result making them the better choice for several pharmaceutical drugs. Additionally, the FDA has approved eight peptides, two oligonucleotides, and two ADCs that consist of peptides out of fifty drugs that were submitted to the FDA in 2021.
• Surge in Usage of Peptides for Curing COVID-19 – As per the research published in August 2022, over 100 peptides were under development for the COVID-19 diagnostics and treatment virus. In this 15 were synthetic peptides for acute respiratory distress syndrome and several other respiratory sicknesses caused by SAES-Cov-2. Basically, peptides are originally obtained from the human body and have the ability to develop into effective therapies due to their potential to focus specific receptors in the body.
• Growing Expenditure by Pharmaceutical Industry on R&D along with Growth in Drug Approvals – Such as, in the United States in 2019 over USD 83 million was spent on research and development by the pharmaceutical sector. Also, the number of new drug-approved sales grew by 60% between 2010 to 2019, which rose compared to the previous decade.
• High Prevalence of Cancer Globally – Reported in 2020 as per American Cancer Society Journal, men had a 19% higher incidence rate of cancer as compared to women. Peptides have been used in multiple cancer cases and have shown relevant results in treatment. Moreover, the high demand for better treatment and therapies for cancer is predicted to boost the market growth in the projected period.
• Development and Approval of Advanced Peptides for Obesity and Weight Gain – As per the US FDA, Imcivree, a pro-opiomelanocortin-derived peptide, was approved for chronic weight management for obese patients with unique genetic circumstances aged six years or above.

Challenges

• Tough Regulatory Framework and Strict Approval Procedure for Peptide-based Products – The difficulty in the regulatory framework and approval procedure makes it tough for companies to bring the latest peptide-based products to market, as the procedure is both time-consuming and high in cost. This creates limitations to the entry of new companies and hamper market expansion in the upcoming future.
• Expensive Raw Materials
• Lack of Knowledge in Peptide Synthesis